Cargando…

Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes

BACKGROUND: CDC25 phosphatases are important regulators of the cell cycle. Their abnormal expression detected in a number of tumors implies that their dysregulation is involved in malignant transformation. However, the role of CDC25s in vulvar cancer is still unknown. To shed light on their roles in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhihui, Trope, Claes G, Flørenes, Vivi Ann, Suo, Zhenhe, Nesland, Jahn M, Holm, Ruth
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887779/
https://www.ncbi.nlm.nih.gov/pubmed/20500813
http://dx.doi.org/10.1186/1471-2407-10-233
_version_ 1782182581538652160
author Wang, Zhihui
Trope, Claes G
Flørenes, Vivi Ann
Suo, Zhenhe
Nesland, Jahn M
Holm, Ruth
author_facet Wang, Zhihui
Trope, Claes G
Flørenes, Vivi Ann
Suo, Zhenhe
Nesland, Jahn M
Holm, Ruth
author_sort Wang, Zhihui
collection PubMed
description BACKGROUND: CDC25 phosphatases are important regulators of the cell cycle. Their abnormal expression detected in a number of tumors implies that their dysregulation is involved in malignant transformation. However, the role of CDC25s in vulvar cancer is still unknown. To shed light on their roles in the pathogenesis and to clarify their prognostic values, expression of CDC25A, CDC25B and CDC25C in a large series of vulvar squamous cell carcinomas were examined. METHODS: Expression of CDC25A, CDC25B, CDC25C and phosphorylated (phospho)-CDC25C (Ser216) were examined in 300 vulvar carcinomas using immunohistochemistry. Western blot analysis was utilized to demonstrate CDC25s expression in vulvar cancer cell lines. Kinase and phosphatase assays were performed to exclude cross reactivity among CDC25s isoform antibodies. RESULTS: High nuclear CDC25A and CDC25B expression were observed in 51% and 16% of the vulvar carcinomas, respectively, whereas high cytoplasmic CDC25C expression was seen in 63% of the cases. In cytoplasm, nucleus and cytoplasm/nucleus high phospho-CDC25C (Ser216) expression was identified in 50%, 70% and 77% of the carcinomas, respectively. High expression of CDC25s correlated significantly with malignant features, including poor differentiation and infiltration of vessel for CDC25B, high FIGO stage, presence of lymph node metastases, large tumor diameter, poor differentiation for CDC25C and high FIGO stage, large tumor diameter, deep invasion and poor differentiation for phospho-CDC25C (Ser216). In univariate analysis, high expression of phospho-CDC25C (Ser216) was correlated with poor disease-specific survival (p = 0.04). However, such an association was annulled in multivariate analysis. CONCLUSIONS: Our results suggest that CDC25C and phospho-CDC25C (Ser216) play a crucial role and CDC25B a minor role in the pathogenesis and/or progression of vulvar carcinomas. CDC25B, CDC25C and phospho-CDC25C (Ser216) were associated with malignant features and aggressive cancer phenotypes. However, the CDC25s isoforms were not independently correlated to prognosis.
format Text
id pubmed-2887779
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28877792010-06-19 Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes Wang, Zhihui Trope, Claes G Flørenes, Vivi Ann Suo, Zhenhe Nesland, Jahn M Holm, Ruth BMC Cancer Research Article BACKGROUND: CDC25 phosphatases are important regulators of the cell cycle. Their abnormal expression detected in a number of tumors implies that their dysregulation is involved in malignant transformation. However, the role of CDC25s in vulvar cancer is still unknown. To shed light on their roles in the pathogenesis and to clarify their prognostic values, expression of CDC25A, CDC25B and CDC25C in a large series of vulvar squamous cell carcinomas were examined. METHODS: Expression of CDC25A, CDC25B, CDC25C and phosphorylated (phospho)-CDC25C (Ser216) were examined in 300 vulvar carcinomas using immunohistochemistry. Western blot analysis was utilized to demonstrate CDC25s expression in vulvar cancer cell lines. Kinase and phosphatase assays were performed to exclude cross reactivity among CDC25s isoform antibodies. RESULTS: High nuclear CDC25A and CDC25B expression were observed in 51% and 16% of the vulvar carcinomas, respectively, whereas high cytoplasmic CDC25C expression was seen in 63% of the cases. In cytoplasm, nucleus and cytoplasm/nucleus high phospho-CDC25C (Ser216) expression was identified in 50%, 70% and 77% of the carcinomas, respectively. High expression of CDC25s correlated significantly with malignant features, including poor differentiation and infiltration of vessel for CDC25B, high FIGO stage, presence of lymph node metastases, large tumor diameter, poor differentiation for CDC25C and high FIGO stage, large tumor diameter, deep invasion and poor differentiation for phospho-CDC25C (Ser216). In univariate analysis, high expression of phospho-CDC25C (Ser216) was correlated with poor disease-specific survival (p = 0.04). However, such an association was annulled in multivariate analysis. CONCLUSIONS: Our results suggest that CDC25C and phospho-CDC25C (Ser216) play a crucial role and CDC25B a minor role in the pathogenesis and/or progression of vulvar carcinomas. CDC25B, CDC25C and phospho-CDC25C (Ser216) were associated with malignant features and aggressive cancer phenotypes. However, the CDC25s isoforms were not independently correlated to prognosis. BioMed Central 2010-05-25 /pmc/articles/PMC2887779/ /pubmed/20500813 http://dx.doi.org/10.1186/1471-2407-10-233 Text en Copyright ©2010 Wang et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wang, Zhihui
Trope, Claes G
Flørenes, Vivi Ann
Suo, Zhenhe
Nesland, Jahn M
Holm, Ruth
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
title Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
title_full Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
title_fullStr Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
title_full_unstemmed Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
title_short Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
title_sort overexpression of cdc25b, cdc25c and phospho-cdc25c (ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887779/
https://www.ncbi.nlm.nih.gov/pubmed/20500813
http://dx.doi.org/10.1186/1471-2407-10-233
work_keys_str_mv AT wangzhihui overexpressionofcdc25bcdc25candphosphocdc25cser216invulvarsquamouscellcarcinomasareassociatedwithmalignantfeaturesandaggressivecancerphenotypes
AT tropeclaesg overexpressionofcdc25bcdc25candphosphocdc25cser216invulvarsquamouscellcarcinomasareassociatedwithmalignantfeaturesandaggressivecancerphenotypes
AT flørenesviviann overexpressionofcdc25bcdc25candphosphocdc25cser216invulvarsquamouscellcarcinomasareassociatedwithmalignantfeaturesandaggressivecancerphenotypes
AT suozhenhe overexpressionofcdc25bcdc25candphosphocdc25cser216invulvarsquamouscellcarcinomasareassociatedwithmalignantfeaturesandaggressivecancerphenotypes
AT neslandjahnm overexpressionofcdc25bcdc25candphosphocdc25cser216invulvarsquamouscellcarcinomasareassociatedwithmalignantfeaturesandaggressivecancerphenotypes
AT holmruth overexpressionofcdc25bcdc25candphosphocdc25cser216invulvarsquamouscellcarcinomasareassociatedwithmalignantfeaturesandaggressivecancerphenotypes